Ninety day adverse events following single level posterior lumbar interbody fusion in patients with sickle cell disease

Meera M. Dhodapkar, Scott J. Halperin, Comron Saifi, Peter Whang, Jonathan N. Grauer, Arya Varthi

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

BACKGROUND CONTEXT: Sickle cell disease (SCD) is an inherited disorder of red blood cells caused by mutation in the hemoglobin beta chain and is the most common inherited genetic disorder in the United States. Postoperative outcomes following single-level posterior lumbar interbody fusion (PLIF) in patients with SCD are not well characterized.

PURPOSE: To examine 90-day postoperative outcomes among a matched cohort of patients with and without SCD who underwent single level PLIF utilizing a national administrative database.

STUDY DESIGN/SETTING: Retrospective database study.

PATIENT SAMPLE: Adult patients without and with SCD who underwent single level PLIF from 2010 to 2021 Q1 were identified and matched 10:1 based on age, sex and ECI. Exclusion criteria included: age <18 years old, recent history of infection, neoplasm, or trauma, as well as not being active in the database for 90 days following their procedure.

OUTCOME MEASURES: Ninety-day postoperative adverse events and emergency department (ED) visits.

METHODS: The matched cohorts were defined, and 90-day adverse event and ED visit rates were compared with univariable analyses and multivariable logistic regression, controlling for age, sex, and Elixhauser comorbidity index (ECI).

RESULTS: Overall, 191,765 PLIF patients were identified, of which SCD was noted for 76 (0.04%). On multivariable analysis of the matched populations, patients with SCD were at increased odds ratio (OR) of the following (in decreasing OR order): transfusion (OR 17.69), pneumonia (OR 6.30), sepsis (OR 4.86), aggregated minor adverse events (OR 4.65), aggregated all adverse events (OR 3.87), ED visits (OR 3.53), and aggregated severe adverse events (OR 2.80) (p<.05 for all).

CONCLUSIONS: The current study examined a relatively small, but largest to date, cohort of SCD patients undergoing PLIF. Patients with this condition were at greater odds of several perioperative adverse events, and these findings may be helpful for patient counselling and surgical planning.

Original languageEnglish (US)
Pages (from-to)807-811
Number of pages5
JournalSpine Journal
Volume24
Issue number5
DOIs
StatePublished - May 2024

Keywords

  • Lumbar fusion
  • National database study
  • Sickle cell disease
  • Surgical outcomes

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Ninety day adverse events following single level posterior lumbar interbody fusion in patients with sickle cell disease'. Together they form a unique fingerprint.

Cite this